This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Fresh Tracks Therapeutics (FRTX) Stock Overview

Does not have significant operations. More details

FRTX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue grew by 15.3% over the past year

Risk Analysis

Does not have a meaningful market cap ($6M)

Latest financial reports are more than 6 months old

Volatile share price over the past 3 months compared to the US market

FRTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW483,421 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

483,421 investors already sharing narratives

View all narratives

Fresh Tracks Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Fresh Tracks Therapeutics
Historical stock prices
Current Share Price	US$0.94
52 Week High	US$1.03
52 Week Low	US$0.03
Beta	0.54
1 Month Change	0.21%
3 Month Change	30.77%
1 Year Change	0.54%
3 Year Change	-89.81%
5 Year Change	-99.05%
Change since IPO	-99.56%

Recent updates

Seeking Alpha • Sep 07

Brickell Biotech changes name to Fresh Tracks Therapeutics

Clinical-stage biotech Brickell Biotech, Inc. (NASDAQ:BBI) announced a major rebranding exercise on Wednesday, renaming its corporate identity to Fresh Tracks Therapeutics, Inc. Accordingly, the company said that BBI’s name, logo, website, and branding would change to reflect the company’s new strategic shift towards autoimmune, inflammatory, and other diseases. In line with the rebranding, the company’s common stock will begin trading under the new Nasdaq ticker symbol “FRTX” from Thursday. Meanwhile, in connection with the rebranding, the company has formed a Scientific Advisory Board (SAB), which comprises experts in immunology and inflammation. SAB will guide the management and board as the company targets autoimmune and inflammatory diseases with early-stage candidate FRTX-02, pre-clinical asset FRTX-10, and the next-generation kinase inhibitor platform. FRTX-02, formerly known as BBI-02, is undergoing a Phase 1 trial for atopic dermatitis with topline data expected in early 2023.

Seeking Alpha • Aug 11

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Brickell Biotech press release (NASDAQ:BBI): Q2 GAAP EPS of -$0.01 beats by $1.43. Revenue of $4.32M (+2780.0% Y/Y) beats by $1.18M. The Company expects its cash and cash equivalents as of June 30, 2022, combined with $2.0 million from expected near-term payments under the APA with Botanix, will support its operations for at least the next 12 months.

Seeking Alpha • Jul 20

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Brickell Biotech (NASDAQ:BBI) was notified by Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing on Nasdaq. The stock will continue to be listed and traded on the exchange. Shares trading 1.4% higher premarket.

Analysis Article • Feb 14

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analysis Article • Jan 06

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

This month, we saw the Brickell Biotech, Inc. ( NASDAQ:BBI ) up an impressive 75%. But that is minimal compensation for...

Shareholder Returns

	FRTX	US Biotechs	US Market
7D	2.7%	-2.4%	2.4%
1Y	0.5%	31.5%	19.6%

Return vs Industry: FRTX exceeded the US Biotechs industry which returned -6.9% over the past year.

Return vs Market: FRTX underperformed the US Market which returned 15.3% over the past year.

Price Volatility

Is FRTX's price volatile compared to industry and market?
FRTX volatility
FRTX Average Weekly Movement	11.3%
Biotechs Industry Average Movement	10.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: FRTX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: FRTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2009	4	Bert Marchio	ir.frtx.com

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Fresh Tracks Therapeutics, Inc. Fundamentals Summary

How do Fresh Tracks Therapeutics's earnings and revenue compare to its market cap?
FRTX fundamental statistics
Market cap	US$5.59m
Earnings (TTM)	-US$5.69m
Revenue (TTM)	US$8.01m

0.7x

P/S Ratio

-1.0x

P/E Ratio

Is FRTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FRTX income statement (TTM)
Revenue	US$8.01m
Cost of Revenue	US$3.18m
Gross Profit	US$4.82m
Other Expenses	US$10.52m
Earnings	-US$5.69m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.95
Gross Margin	60.25%
Net Profit Margin	-71.12%
Debt/Equity Ratio	0%

How did FRTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/03 02:40
End of Day Share Price	2025/02/28 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fresh Tracks Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raghuram Selvaraju	H.C. Wainwright & Co.
Thomas Flaten	Lake Street Capital Markets, LLC
Leland Gershell	Oppenheimer & Co. Inc.

This company listing is no longer active

Fresh Tracks Therapeutics (FRTX) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Fresh Tracks Therapeutics, Inc. Competitors

Soligenix

Xenetic Biosciences

BioXcel Therapeutics

Marizyme

Price History & Performance

Recent News & Updates

Fresh Tracks Therapeutics Announces Special Distribution

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Recent updates

Fresh Tracks Therapeutics Announces Special Distribution

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Price target increased to US$72.50

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus estimates of losses per share improve by 25%

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Brickell Biotech changes name to Fresh Tracks Therapeutics

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Consensus revenue estimates increase by 26%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Consensus revenue estimates increase by 159%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus revenue estimates fall by 47%

Price target decreased to US$2.67

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought US$134k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

CEO & Director recently bought US$118k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Brickell Biotech, Inc. to Report Q4, 2020 Results on Mar 09, 2021

New 90-day high: US$1.38

New 90-day high: US$1.29

Brickell Biotech, Inc. Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (Ecclock®)